- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Mehmet Asim Bilen, MD | Authors
Clinical Pearls on Recent Advances and the Future of Treatment in RCC
June 02, 2022
Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Reflections on Novel Targets and Emerging Regimens for RCC
June 02, 2022
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
June 02, 2022
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
The Importance of Team-Based Management and Patient Communication
May 25, 2022
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
May 25, 2022
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Considerations for Patient-Focused, Shared Decision-Making in RCC
May 18, 2022
Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.
Patient-Specific Factors Impacting Treatment Choices in RCC
May 18, 2022
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
Strategies for Prevention and Management of Adverse Events
May 11, 2022
Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.
Balancing Treatment Efficacy with Toxicity in Metastatic RCC
May 11, 2022
David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.
Common Adverse Events with Single-Agent or Combination Therapy
May 05, 2022
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.